T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin-Reference-Cited by-同舟云学术

T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin

Published:2024-06-10 Issue: Volume: Page:
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Liu Jun-jun,Pan Zhi-di,Yue Ya-li,Wang Shu-sheng,Chen Jie,Jiang Hua,Zhang Bao-hong,Wu Ming-yuan,Yuan Yun-sheng,Bian Yan-lin,Yin Hai-yang,Wang Lei,Li Jun-yan,Gilly John,Xie Yue-qing,Zhu Jian-wei

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41401-024-01316-6.pdf

Reference52 articles.

1. Lugtenburg P, Mous R, Clausen MR, Chamuleau ME, Johnson P, Linton K, et al. First-in-human, phase 1/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody®-CD3 × CD20) in B-cell non-Hodgkin lymphomas. Blood. 2019;134:758.

2. Lim EA, Schweizer MT, Chi KN, Aggarwal RR, Agarwal N, Gulley JL, et al. Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40:279.

3. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20 × CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9:e327–e39.

4. Weidanz J. Targeting cancer with bispecific antibodies. Science. 2021;371:996–7.

5. Kang C. Mosunetuzumab: first approval. Drugs. 2022;82:1229–34.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09